Preferred Label : Elraglusib;
NCIt synonyms : Glycogen Synthase Kinase-3 Inhibitor 9-ING-41;
NCIt related terms : GSK-3 Inhibitor 9-ING-41;
NCIt definition : A maleimide-based, small molecule inhibitor of glycogen synthase kinase-3 (GSK-3;
serine/threonine-protein kinase GSK3) with potential antineoplastic activity. Upon
intravenous administration, elraglusib binds to and competitively inhibits GSK-3,
which may lead to downregulation of nuclear factor kappa B (NF-kappaB) and decreased
expression of NF-kappaB target genes including cyclin D1, B-cell lymphoma 2 (Bcl-2),
anti-apoptotic protein XIAP, and B-cell lymphoma extra-large (Bcl-XL). This may inhibit
NF-kappaB-mediated survival and chemoresistance in certain tumor types. GSK-3, a constitutively
active serine/threonine kinase that plays a role in numerous pathways involved in
protein synthesis, cellular proliferation, differentiation, and metabolism, is aberrantly
overexpressed in certain tumor types and may promote tumor cell survival and resistance
to chemotherapy and radiotherapy.;
UNII : ND1SOF0DLU;
CAS number : 1034895-42-5; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1034895-42-5
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Molecule name : 9-ING-41; 9 ING 41;
NCI Metathesaurus CUI : CL935798;
Origin ID : C156792;
UMLS CUI : C5554553;
Semantic type(s)
- concept_is_in_subset
- has_target
